Cold autoimmune hemolytic anemia

Cold Agglutinin Disease 2020 Market Spotlight - Licensing and Asset Acquisition Deals - ResearchAndMarkets.com

Retrieved on: 
Friday, July 3, 2020
Health, Pharmaceutical, Acquired hemolytic anemia, Health, Autoimmune diseases, Medical specialties, Antibodies, Cold agglutinin disease, Agglutinin, Sanofi, Clinical trial, Sutimlimab, Cold autoimmune hemolytic anemia

This Market Spotlight report covers the Cold Agglutinin Disease market, comprising disease background and treatment information, key pipeline drugs, clinical trials, probability of success, licensing and acquisition deals, and an epidemiology overview.

Key Points: 
  • This Market Spotlight report covers the Cold Agglutinin Disease market, comprising disease background and treatment information, key pipeline drugs, clinical trials, probability of success, licensing and acquisition deals, and an epidemiology overview.
  • There are only two industry-sponsored drugs in active clinical development for cold agglutinin disease, with one drug each in Phase II and Phase III
    Therapies in development for cold agglutinin disease target the complement pathway.
  • There have been only two licensing and asset acquisition deals involving cold agglutinin disease drugs during 2015-20.
  • Sanofi leads industry sponsors with the highest number of clinical trials for cold agglutinin disease.

FDA grants priority review of sutimlimab, potential first approved treatment of hemolysis in adult patients with Cold Agglutinin Disease

Retrieved on: 
Thursday, May 14, 2020
Autoimmune diseases, Medical specialties, Acquired hemolytic anemia, Life sciences, Health, Cold autoimmune hemolytic anemia, Monoclonal antibodies, Cold agglutinin disease, Sutimlimab, Food and Drug Administration, Biopharmaceutical, Cold sensitive antibodies

FDA grants priority review of sutimlimab, potential first approved treatment of hemolysis in adult patients with Cold Agglutinin Disease

Key Points: 
  • FDA grants priority review of sutimlimab, potential first approved treatment of hemolysis in adult patients with Cold Agglutinin Disease
    PARIS May 14, 2020 - The U.S. Food and Drug Administration (FDA) has granted priority review of Sanofis Biologics License Application (BLA) for sutimlimab for the treatment of hemolysis in adult patients with cold agglutinin disease (CAD).
  • Sutimlimab, an investigational monoclonal antibody, targets the underlying cause of hemolysis in CAD by selectively inhibiting complement C1s.
  • If approved, sutimlimab would be the first and only approved treatment for these patients.
  • If approved, sutimlimab will be the first and only FDA-approved treatment to uniquely address C1-activated hemolysis and help alleviate the chronic disease burden for people with CAD.

Cold Agglutinin Disease (CAD) Epidemiology Forecast to 2028: Focus on 10 Emerging Markets - Turkey, Russia, Saudi Arabia, UAE, Mexico, Colombia, Brazil, Argentina, China, and Taiwan - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 7, 2019
Health, General Health, Autoimmune diseases, Acquired hemolytic anemia, Geography of Asia, Cold autoimmune hemolytic anemia, Countries, Antibodies, Cold agglutinin disease, Agglutinin, Western Asia, United Arab Emirates

The "Cold Agglutinin Disease (CAD) - Epidemiology Forecast - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cold Agglutinin Disease (CAD) - Epidemiology Forecast - 2028" report has been added to ResearchAndMarkets.com's offering.
  • Cold Agglutinin Disease (CAD)- Epidemiology Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology trends of CAD in 10 Emerging Markets (EM) i.e.
  • Turkey, Russia, Saudi Arabia, United Arab Emirates (UAE), Mexico, Colombia, Brazil, Argentina, China, and Taiwan.
  • The total prevalent cases for Cold Agglutinin Disease (CAD) were highest in China, while Russia and U.A.E.

CoolSculpting® and Sonja Morgan Talk Bikini Denial Just In Time For Summer

Retrieved on: 
Thursday, March 21, 2019
Medicine, Acquired hemolytic anemia, Clinical medicine, Medical specialties, Autoimmune diseases, Cold autoimmune hemolytic anemia, Plastic surgery, Cold agglutinin disease, Paroxysmal cold hemoglobinuria, Fat removal procedures, Cryoglobulinemia, Bikini

CoolSculpting the treatment doctors use most for non-invasive fat removal targets that unwanted fat without surgery and little to no downtime.

Key Points: 
  • CoolSculpting the treatment doctors use most for non-invasive fat removal targets that unwanted fat without surgery and little to no downtime.
  • Visit www.CoolSculpting.com to learn more about how to say "bye-bye" to Bikini Denial and get ready to hit the beach this summer!
  • Consumers can share their own Bikini Denial stories on social media using #BikiniDenial and also enter the Bikini Denial Sweepstakes for a chance to win a free CoolSculpting treatment.
  • You should not have the CoolSculpting procedure if you suffer from cryoglobulinemia, cold agglutinin disease, or paroxysmal cold hemoglobinuria.